WAVEMAN · COMPANY
ETRA · Electra Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.26% 13F +439META-2.43% 13F +2,704RCG-0.59% CLUSTERUTHR-0.53% 13F +427CRWV+1.85% 13F +694CRM-2.03% 13F +1,024CVNA-1.11% 13F +799DELL-3.46% 13F +1,208TPL+1.58% 13F +443NET-3.10% 13F +713MSTR+16.39% 13F +525CRWD-3.28% 13F +1,384ANET+3.02% 13F +1,327COIN+11.66% 13F +475TEAM-0.26% 13F +439META-2.43% 13F +2,704RCG-0.59% CLUSTERUTHR-0.53% 13F +427CRWV+1.85% 13F +694CRM-2.03% 13F +1,024CVNA-1.11% 13F +799DELL-3.46% 13F +1,208TPL+1.58% 13F +443NET-3.10% 13F +713MSTR+16.39% 13F +525CRWD-3.28% 13F +1,384ANET+3.02% 13F +1,327COIN+11.66% 13F +475
← ALL COMPANIES

ETRA

Electra Therapeutics, Inc.
CIK 0002088082
SEC FILINGS☆ WATCH
INSIDER NET · 180D
$40.0M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
2
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
CONVERSIONS · 180D
12
codes C/M, not in net · no price filed

WaveMan Stock Sonar 1/7 axesFind similar shapesCompare

Insider conviction
90
inputs
  • Net open-market buying, 180d$40.0M · 99 pct, universe of 3,459
  • Insider buyers, 180d2 · 80 pct, universe of 3,480
6 not measured: Profitability, Financial health, Growth, Institutional and government, Risk and compliance, Innovation
  • Profitability needs 2 of 4 inputs, 0 present: not filed
  • Financial health needs 1 of 2 inputs, 0 present: not filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • Risk and compliance needs 1 of 4 inputs, 0 present: needs two 10-Ks with a Risk Factors section (not 20-F filers or stubs); no short interest or no free float on file; revenue under $50M or not filed, so a count cannot be scaled to size
  • Innovation needs 1 of 1 inputs, 0 present: patent data not loaded yet

1 of 7 axes scored, each a percentile against sector peers (universe where the sector is thin). Higher is better on every axis; an unscored axis is unmeasured, not a low score. How it is scored

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$40.0M over 180 days
+$40.0M over 90 days · +$40.0M of it by a 10%+ holder
the highest in its sector
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
no short interest reported

Watch ETRA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Watch ETRA, free
Live price
Daily candles from TradingView, on their licence , no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $40.0M bought by insiders over 180 days. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Insider transactions
Form 4 purchases and sales (codes P and S), grants, option exercises and preferred conversions excluded

Over the last 180 days, Electra Therapeutics, Inc. insiders bought a net $40.0M of stock across 4 Form 4 purchases and sales, with 2 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-24.

INSIDER
FILED
SHARES
VALUE
ORBIMED ADVISORS LLC
Director
BUY
2026-09-21
333,333
$5.0M
ORBIMED ADVISORS LLC
Director
BUY
2026-09-21
1,000,000
$15.0M
GORDON CARL L
Director
BUY
2026-09-21
333,333
$5.0M
GORDON CARL L
Director
BUY
2026-09-21
1,000,000
$15.0M
4 TRANSACTIONS ON RECORD · THIN RECORD, READ IT AS SUCH

Showing the most recent few. Create a free account to use the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.